Talacotuzumab is an IgG1 CD123-Neutralizing Monoclonal Antibody
Interleukin-3 receptor (CD123) is a soluble cytokine that is important for the immune system. CD123 is the receptor of interleukin 3 α Chain is a cytokine receptor. Meanwhile, CD123 is overexpressed in a variety of hematological malignancies. Compared with non-tumor hematopoietic stem cells, CD123 expression was high in leukemia...
Urabrelimab (SRF231) is a Fully Human Anti-CD47 Monoclonal Antibody
CD47 (Cluster of Differentiation 47) is a transmembrane protein, belonging to the immunoglobulin superfamily. It can interact with signal-regulatory protein alpha (SIRPα) which is an inhibitory transmembrane receptor present on myeloid cells. The interaction leads to different cell-to-cell responses, such as phagocytosis inhibition, cell-cell fusion stimulation, and T-cell activation....
Benufutamab (GEN1029) is a DR5-Specific Agonistic Antibody for Solid Tumor Research
Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) and TNFR superfamily member 10B (TNFRSF10B), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Triggering of these receptors via TRAIL or agonistic antibodies selectively induced apoptosis in malignant cells derived from...
Xentuzumab is a Monoclonal Antibody That Targets IGF Ligands IGF1 and IGF2
IGF, an insulin-like growth factor, regulates cell growth, proliferation, and survival. The IGF system is made up of IGF1, IGF2, insulin, and corresponding receptors. It transmits abnormal signals to cause a variety of cancers. One that stands out is castration-resistant prostate cancer. IGF can either up-regulate IGF-binding proteins or...
Mogamulizumab is a Defucosylated Anti-CCR4 Monoclonal Antibody
C-C Motif Chemokine Receptor 4 (CCR4) is a G-coupled-protein receptor for C-C chemokines. It’s on surface of tumor cells in leukemia and lymphoma patients. For example, adult T-cell leukemia-lymphoma (ATLL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) all expresses CCR-4. Furthermore, leukemia and lymphoma are clinically and...
Tiragolumab is An Immune Checkpoint Inhibitor Binding to T-cell Immunoglobulin and TIGIT
Tiragolumab is a potent TIGIT inhibitor. Tiragolumab alone or in combination with the PD-L1 inhibitor Atezolizumab has effects on solid cancers. Additionally, at two recent medical meetings, the agent achieves statistically significant results in multiple solid malignancies. Especially in small cell lung cancer (NSCLC). Lung cancer is the most...